Skip to Main Content

Key negotiations that helped seal Gilead Science’s $21 billion purchase of Immunomedics, announced Sunday, took place on the makeshift patio of a suburban New Jersey restaurant during a socially distanced dinner two weeks ago, separated from a highway by some hedges.

Immunomedics’ Executive Chairman Behzad Aghazadeh, eating at a restaurant for the first time since the Covid-19 pandemic struck, ordered lamb chops. Gilead CEO Daniel O’Day had steak. They requested a table away from other diners in order to be discreet. But the main thing on the menu, from Gilead’s perspective, was Trodelvy, Immunomedics’ recently approved drug to treat women with triple-negative breast cancer, a particularly aggressive form of the disease with few treatment options. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.